Induction of Epstein-Barr virus antigens by hydroxyurea.
Treatment of the Epstein-Barr virus (EBV)-transformed, virus-producer P3HR-1 cell line with hydroxyurea (HU) resulted in increased synthesis of the EBV-specific early antigen (EA) and viral capsid antigen (VCA). The induction was noted already at a 200 mumol/l and reached plateau at a 1500 mumol/l HU concentration. At plateau concentration, the percentage of cells expressing EA and VCA was about 5 times higher than in the absence of the drug.
D000956:Antigens, Viral / Q000096:biosynthesis; D002213:Capsid / Q000096:biosynthesis; D036022:Capsid Proteins; D004854:Herpesvirus 4, Human / Q000187:drug effects / Q000254:growth & development*; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology*; D014764:Viral Proteins / Q000096:biosynthesis*; D014775:Virus Activation / Q000187:drug effects*
D000956:Antigens, Viral; D036022:Capsid Proteins; C041788:Epstein-Barr viral capsid antigen; C033305:Epstein-Barr virus early antigen; D014764:Viral Proteins; D006918:Hydroxyurea